Kornimate/medical-research-clean huggingface dataset:
endothelial function in human arteries

Conditions: Endothelial Dysfunction

Summary: up to 30 patients with lower extremity disease scheduled to undergo diagnostic angiography will undergo baseline bloodwork and ivus (intravascular ultrasound), followed by dosing with l-arginine to assess changes in endothelial function.

we will assess doses of regional l-arginine supplementation in patients undergoing elective angiography for lower extremity pad. assessment of edr and eir with ivus in patent arteries will be performed with one of 3 doses of catheter-directed l-arginine. we will obtain plasma samples from the peripheral arteries and assay amino acid levels and protein oxidation products using mass spectrometry. these experiments will determine the optimal l-arginine supplementation dose to be used in further studies. we expect to show that l-arginine supplementation will have a more significant effect on vessels less affected by atherosclerosis, but that this effect diminishes with greater atheroma accumulation as measured by ivus virtual histology. also, we expect l-arginine supplementation to be most effective in vessels with low baseline l-arginine levels. lastly, we will compare local arterial factors obtained via catheter-directed arterial sampling (nox, l-arginine, nitrotyrosine levels) to traditional serum risk factors (glucose, hba1c, ldl, homocysteine and hs c-reactive protein).

Eligibility criteria:
inclusion criteria: * age \>18 years * symptoms of intermittent claudication, rest pain or minor tissue loss (rutherford category i-v) * abi of \<.90 * angiographic demonstration of a 100mm patent segment of superficial femoral artery containing at least one distal runoff vessel exclusion criteria: * acute limb ischemia, * contraindication to angiography (creatinine \>2.5) * concurrent oral anticoagulant therapy that cannot be safely withheld * extensive tissue loss or gangrene

Keywords: peripheral vascular disease endothelial dysfunction intravascular ultrasound l-arginine
voxx human performance technology socks for chemotherapy-induced peripheral neuropathy

Conditions: Neuropathy;Peripheral; Chemotherapy-induced Peripheral Neuropathy; Neuropathy

Summary: this is a double blind, randomized, crossover pilot study of voxx human performance technology socks versus placebo socks for the treatment of chemotherapy-induced peripheral neuropathy in patients with cancer. patients will be randomized 1:1 to one of the following regimens: * arm a: continuous wear of voxx human performance technology socks for 2 weeks, followed by continuous wear of placebo socks for 2 weeks (separated by a 2-week washout period) * arm b: continuous wear of placebo socks for 2 weeks, followed by continuous wear of voxx human performance technology socks for 2 weeks (separated by a 2-week washout period) patients will be evaluated at three time points using an objective neuropathy assessment as well as self-report questionnaires assessing chemotherapy-induced peripheral neuropathy, quality of life, and cancer-related symptoms.


Eligibility criteria:
inclusion criteria: * diagnosed with cancer, stage 1-4. * completed taxane- or platinum-based chemotherapy, vinca alkaloids, or bortezomib at least three months (90 days) ago. current use of anti-estrogen therapy, herceptin, or parp inhibitors is okay. * clinical diagnosis of chemotherapy-induced peripheral neuropathy by clinician. this will be based on symptom history (paresthesias, dysesthesias, allodynia), loss of deep tendon reflexes, decreased vibratory sensation, or the presence of symmetrical stocking-glove numbness or paresthesias beginning after neurotoxic chemotherapy. * self-reported average neuropathic pain score of at least 4 on a 10-point scale over the past 1 month. * age ≥ 18 years * concomitant use of analgesics is permitted if the dose has been stable for at least 2 weeks prior to study enrollment (no new analgesics have been added, discontinued, or changed in the 2 weeks prior to randomization). * written informed consent obtained from subject and ability for subject to comply with the requirements of the study. exclusion criteria: * syphilis, alcoholic neuropathy, diabetic neuropathy, neurological disorders, brain injury, or stroke, as assessed by the treating physician. * neuropathy related to abnormal thyroid stimulating hormone or cobalamin levels as assessed by treating physician. * current severe depression, suicidal ideation, bipolar disease, alcohol abuse, or major eating disorder, as assessed by the treating physician. * currently participating in another chemotherapy-induced peripheral neuropathy-targeted program or trial. * participated in a non-pharmacologic therapy specifically for the treatment of chemotherapy-induced peripheral neuropathy, including scrambler therapy, mindfulness meditation, or other mind-body activities within 14 days (2 weeks) prior to randomization.

Keywords: chemo-induced peripheral neuropathy voxx socks voxx human performance technology voxx hpt
a study of nivolumab combined with ipilimumab versus nivolumab alone in participants with advanced kidney cancer

Conditions: Renal Cell Carcinoma

Summary: the purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * histological confirmation of renal carcinoma with clear cell component including participants who may have sarcomatoid features. * advanced (not amenable to curative surgery or radiation therapy) renal cell carcinoma (rcc) or metastatic rcc (mrcc). * measurable disease by computed tomography (ct) or magnetic resonance imaging (mri) per response evaluation criteria in solid tumors version 1.1 (recist 1.1) criteria. * no prior systemic therapy for rcc * must be intermediate or poor risk as per international metastatic rcc database consortium (imdc). exclusion criteria: * any active central nervous system (cns) metastases. * active, known, or suspected autoimmune disease. * prior treatment with an anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, anti-ctla-4 antibody, or any other agents specifically targeting t-cell co-stimulation or checkpoint pathways other protocol-defined inclusion/exclusion criteria apply
inpatient exposure therapy and response prevention & cognitive remediation therapy for anorexia nervosa

Conditions: Anorexia Nervosa

Summary: exposure and response prevention (an-exrp) will help individuals with anorexia nervosa improve their eating behavior.

anorexia nervosa (an) is a serious illness associated with substantial morbidity and a mortality rate among the highest of any psychiatric illness. the rate of relapse is disturbingly high, with up to 50% of patients requiring re-hospitalization within a year of discharge. current treatments are inadequate in helping older adolescents and adults achieve sustained recovery. importantly, eating behavior remains disturbed after weight restoration: patients demonstrate restrictive eating in their self-selected foods and in standardized meals, and caloric intake in standardized meals is inversely related to pre-meal anxiety. emerging data suggest that eating behavior is particularly important in post-hospital course, and that significantly altering eating behavior is critical in improving outcome for these individuals. furthermore, caloric intake in standardized meals has been shown to be related to pre-meal anxiety. this study evaluates the potential utility of two psychotherapeutic interventions in improving eating behavior prior to hospital discharge. each individual receives, in random order, cognitive remediation therapy for 4 weeks and exposure and response prevention for an for 4 weeks. the investigators hypothesize that these interventions will lead to improvement in eating behavior, measured by food diaries and standardized meals.

Eligibility criteria:
inclusion criteria: 1. dsm-iv-tr™ diagnosis of anorexia nervosa (restricting or binge-purge subtype), with or without amenorrhea at the time of inpatient admission 2. subjects will have achieved 85% of ideal body weight (ibw) 3. age 16-45 years 4. no acute medical condition 5. subjects must have signed informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. exclusion criteria: 1. psychotic or bipolar i disorder 2. substance abuse or dependence in the last 6 months 3. current axis i disorder requiring psychotropic medication (ongoing antidepressant treatment for stable comorbid conditions will be allowed) 4. significant co-morbid depression 5. significant medical problems that would introduce additional risk related to research or interfere with participation, e.g. sbp\>140, dbp\>90, hr\>100 for a sustained period. 6. active suicidal intent
a comparison of 000-0551 lotion versus vehicle lotion in subjects with plaque psoriasis (study -304)

Conditions: Plaque Psoriasis

Summary: this phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 lotion and vehicle lotion applied twice daily for two weeks in subjects with plaque psoriasis.


Eligibility criteria:
inclusion criteria: * subject has a clinical diagnosis of stable plaque psoriasis involving a minimum of 2% and no more than 12% affected body surface area. * subject has an investigator's global assessment (iga) score of at least three (moderate) at study start. * if subject is a woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control for the duration of the study. exclusion criteria: * subject has spontaneously improving or rapidly deteriorating plaque psoriasis. * subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis. * subject has used any phototherapy (including laser), photo-chemotherapy or other forms of photo based therapy for the treatment of their psoriasis within 30 days prior to study start. * subject has used any systemic methotrexate, retinoids, systemic corticosteroids \[including intralesional, intra-articular, and intramuscular corticosteroids\], cyclosporine or analogous products within 90 days prior to study start. * subject has used any systemic biologic therapy (i.e., fda-approved or experimental therapy) within five half-lives of the biologic prior to study start. * subject had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to study start or is intending to have such exposure during the study. * subject has used topical body (excluding the scalp) psoriasis therapy (including coal tar, anthralin, steroids, retinoids, vitamin d analogs) within 14 days prior to study start. * subject has used emollients/moisturizers on areas to be treated within four hours prior to clinical evaluation at study start. * subject is currently using lithium or plaquenil (hydroxychloroquine). * subject is currently using a beta-blocking medication (e.g., propanolol) or angiotensin converting enzyme (ace) inhibitor at a dose that has not been stabilized. * subject is pregnant, lactating, or is planning to become pregnant during the study. * subject is currently enrolled in an investigational drug or device study. * subject has used an investigational drug or investigational device treatment within 30 days prior to study start. * subject has been previously enrolled in this study and treated with a test article.

Keywords: psoriasis lotion investigator's global assessment
effects of core stability combined with diaphragmatic strengthening exercises among asthmatic patients

Conditions: Mild Intermittent Asthma

Summary: this is a quasi intervention study evaluating the effects of core stabilization exercises and diaphragmatic strengthening on thoracic kyphosis angle, diaphragmatic excursion, chest expansion, lung functioning (fev1/fvc ratio) and quality of life, in individuals with mild intermittent or mild persistent asthma.

this study evaluated the effects of core stabilization exercises and diaphragmatic strengthening on thoracic kyphosis angle, diaphragmatic excursion, chest expansion, lung functioning (fev1/fvc ratio), and quality of life in individuals with mild intermittent or mild persistent asthma. thirty-seven participants from fauji foundation hospital rawalpindi underwent assessments before and after an 18-session treatment regimen over three weeks. the measures included diaphragmatic excursion, thoracic kyphotic angle, chest expansion, spirometry, and asthma quality of life questionnaire. statistical analysis was performed using spss version 21

Eligibility criteria:
inclusion criteria: * age group: 18-34 years old * both males and females * individuals diagnosed with well controlled mild intermittent asthma or mild persistent asthma, at least six months prior based on referral from pulmonologist. * individuals who have weak core muscles * participating to the study in a voluntary basis exclusion criteria: * level 3 and above asthmatics or status asthmaticus * any congenital deformities of chest wall * demonstrated neuromuscular or neurological deficit/disease of chest wall. * cardiopulmonary diseases including coronary artery disease, heart failure nyha classification, valvular heart disease, cardiomyopathy, arrythmias, interstitial lung disease, copd, pulmonary embolism, pulmonary hypertension, cancers, etc. * any recent cardiothoracic or abdominal surgery or sternotomy * recent history of the blunt chest wall or abdominal trauma * unstable hemodynamic parameters (arterial pressure \>140mmhg systolic and \>90mmhg for diastolic * pregnancy * previous or parallel participation in interventional programs * any psychiatric illnesses
fat injection for rectocele treatment: a novel approach

Conditions: Rectocele; Pelvic Organ Prolapse; Obstructive Defecation Syndrome

Summary: this clinical trial aims to evaluate the effectiveness of autologous fat grafting as a novel treatment for rectocele, a condition characterized by the herniation of rectal tissue into the posterior vaginal wall. women aged 18 to 60 years with mild to moderate rectocele, presenting with symptoms such as obstructive defecation or vaginal bulge, will undergo submucosal fat injections. the study will assess the procedure\&#39;s ability to alleviate symptoms and reduce prolapse recurrence. this prospective, single-arm trial will be conducted at cairo university hospitals.


Eligibility criteria:
inclusion criteria: * female patients aged between 18 and 60 years. * diagnosis of rectocele confirmed by defecography, with a rectocele size of 2 cm (mild) to 4 cm (moderate). * presenting with symptoms of obstructive defecation syndrome, including constipation, incomplete defecation, and/or vaginal bulge. * able to provide written informed consent to participate in the study. exclusion criteria: * patients who have previously undergone surgical repair of rectocele. * presence of thrombosed hemorrhoids. * history of sclerotherapy injection for rectocele. * diagnosis of anal stenosis. * history of coagulopathy or current use of anticoagulant or antiplatelet medications. * refusal or inability to provide informed consent.

Keywords: rectocele pelvic floor dysfunction fat grafting autologous fat injection obstructive defecation pelvic organ prolapse vaginal bulge
the effect of chloroquine in the treatment of patients with dengue

Conditions: Dengue

Summary: the objective of this study was to evaluate the effect of chloroquine in the treatment of patients with dengue.


Eligibility criteria:
inclusion criteria: * patients suspected of having dengue disease * patients were included in the study if they presented with fever and at least two other symptoms, such as: * headache * pain behind the eyes * muscle and bone or joint pains * nausea * vomiting * rash associated to dengue for less than 72 hours exclusion criteria: * pregnant * younger than 18-years old * either cardiac or neurologic disease
the effect of doppler ultrasound on calcified tendinitis

Conditions: Calcific Tendinitis of Shoulder

Summary: calcific tendinitis of the shoulder, is a self-limiting disease characterized by the deposition of calcium phosphate crystals in the rotator cuff tendons. patients will develop complications such as decreased range of motion of the shoulder joint, and thus reducing their quality of life. the most common site of occurrence is 1.5-2 cm away from the supraspinatus tendon insertion site on the greater tuberosity. the primary treatment for calcific tendinitis is conservative, such as non-steroidal anti-inflammatory analgesics for pain relieving, extracorporeal shock wave therapy, subacromial steroid injections, ultrasound-guided barbotage technique for aspirating and washing out calcific deposits. ultrasound is being used in calcified tendinitis for evaluating its size, location, quality, and also using the color doppler ultrasonography to evaluate its reactive inflammatory changes. however, the use of color doppler ultrasonography in diagnosing and treating a shoulder pain with calcification is not being concluded yet. therefore, the aim of this study is to evaluate the efficacy of color doppler ultrasonography in calcified tendinitis.

purpose: to evaluate the efficacy of color doppler ultrasonography in calcified tendinitis.

Eligibility criteria:
inclusion criteria: 1. chronic shoulder pain for more than 1 month 2. shoulder x-ray showed calcified deposit exclusion criteria: 1. patient with needle phobia 2. patient with known allergy to medication like triamcinolone and lidocaine

Keywords: doppler ultrasound
bay1003803 formulation comparison in open psoriasis plaque test

Conditions: Psoriasis

Summary: to explore the efficacy and safety of four bay1003803 formulations by means of a within subject comparison in an open psoriasis plaque test


Eligibility criteria:
inclusion criteria: * male and female (non-childbearing potential) volunteer with stable plaque-type psoriasis, but otherwise healthy * age: 18-64 years exclusion criteria: * severe disease within the last 4 weeks prior to the first study drug administration as determined by the investigator * any topical antipsoriatics on plaques potentially to be treated in this trial (including corticosteroids, vitamin d analogues, immunomodulators, retinoids, dithranol and tar, except for salicylic acid (pretreatment) in the 4 weeks before first treatment and/or planned during the trial, except for allowed topical treatment on the face, ears and scalp * systemic treatment depending on kind of treatment within 4 weeks and 6 months prior and/or planned during the trial * treatment with concomitant medication that may affect and provoke or aggravate psoriasis, e.g. antimalarial drugs, lithium, beta-blockers or angiotensin-converting-enzyme inhibitors (aec inhibitors) unless on a stable dose for 3 months before study medication initiation * clinico-chemical parameters of clinically significant deviation

Keywords: plaque form psoriasis vulgaris
nicotine patch bioequivalence study

Conditions: Healthy Smokers

Summary: the purpose of this study is to compare the relative bioavailability of nicotine following single application of a new transdermal formulation to that of a reference formulation. 4 single 24hour applications separated by 48hour intervals.


Eligibility criteria:
inclusion criteria: * healthy subject aged 18 to 45 years (inclusive) * current smoker of \>or = 5 and \< or = 15 cigarettes/day * fagerström score \< or =5 at selection * absence of any clinically significant abnormal finding at physical, vital sign, electrocardiogram ecg, biological examinations in the investigator's opinion. exclusion criteria: * presence of any significant medical finding or significant history (in particular any cardio-vascular disease, severe renal or hepatic insufficiency, current gastric or duodenal ulcer) that may impact the safety, the interpretation of the results and/or the participation of the subject in the study according to the opinion of the investigator * any visible skin disorder, abnormal skin pigmentation or dermatologic disease liable to interfere with use or assessment of transdermal patch

Keywords: smoking cessation nicotine tobacco use disorder central nervous system agents
effect of vernonia cinerea lozenges as a smoking cessation aid in patients with non-communicable diseases

Conditions: Smoking Cessation

Summary: vernonia cinerea is an herbal which has been recorded in many thai herbal formulation and thai traditional medicine has used this herbal for treating various diseases included hypertension, asthma, fever, hepatitis, kidney stone and smoking cessation. now aday there are more interest for using vernonia cinerea as a medication to aid smoker to quit smoking because it is cheaper than other current therapeutic medications. the objective of this study is to evaluate efficacy and safety of vernonia cinerea lozenge for smoking cessation when compared to placebo.

this study is a multicenter randomized, paralleled, double blind, controlled trial. this study will include 260 patients from lerdsin hospital, chest institute, phramongkutklao hospital, maharaj nakorn chiang mai hospital and paolo memorial phaholyothin hospital who would like to quit smoke. patients will be assigned into two groups, vernonia cinerea group (n=130) and placebo group (n=130), both groups will be instructed to take one lozenge three times a day for three months. the two groups will receive individual counseling about smoking cessation technique by trained healthcare professional on every visit. the main primary outcome for this study is continuous abstinence rate (car), define as self-report of no cigarette smoking, not even a puff since target quit date, plus passed biochemical validation for 1 month.

Eligibility criteria:
inclusion criteria: * age at least 18 years old * have at least 1 underlying non-communicable disease include hypertension, diabetes, dyslipidemia, cardiovascular diseases, cerebrovascular diseases, stable asthma (defined as no asthmatic exacerbation for the preceding 4 weeks necessitating oral prednisolone or an increased use of inhaled corticosteroid, the use of rescue treatment no more than three times a week, and with no clinical indication for change in treatment medication) copd stage a-c according to gold guideline, chronic kidney diseases * smoke 10 cigarettes or over per day at least 1 month prior to study * desired to quit smoking * consent to participate in study exclusion criteria: * renal dysfunction (gfr \< 30 ml/mins/1.73m2) * liver dysfunction (child-pugh score c) * hyperkalemia (serum potassium ≥ 5 meq/l) * documented of active depression or psychosis * active cancer * history of acute coronary syndrome in previous 4 weeks * known case of pregnancy or lactation * use other tobacco products or other addictive substances except alcohol * use other smoking cessation drugs

Keywords: smoking cessation vernonia cinerea non-communicable disease